focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: RWS and James Cropper sink on profit warnings

Wed, 23rd Mar 2022 11:21

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

4D Pharma PLC, up 37% at 61.45 pence, 12-month range 24.46p-135.00p. The pharmaceutical company says its therapeutic treatment MRx0518, in combination Merck's Keytruda, met its primary efficacy endpoint ahead of trial enrolment completion.

----------

AIM - LOSERS

----------

RWS Holdings PLC, down 27% at 342.00p, 12-month range 326.00p-701.00p. The technology-enabled language services provider warns its annual performance is set to be at the lower end of expectations.

RWS will no longer provide services or technology to Russian-owned businesses, and also expects reduced demand for translation into Russian from non-Russian owned companies. As a result, revenue growth from the Language Services unit is set to moderate, and RWS's overall performance for the year is anticipated to be at the lower end of market expectations.

----------

James Cropper PLC, down 18% at 1,002.00p, 12-month range 1,002.00p-1,650.00p. Shares in the paper products manufacturer hit a 12-month low as it warns it will miss previous expectations for profit. For the year ending March 26, James Cropper notes 30% growth in sales, ahead of prior market expectations due to strong demand across all divisions. However, it now expects adjusted pretax profit of GBP3.5 million, a sharp rise from GBP1.1 million the year before, but below prior expectations of GBP4.9 million. This is due to the conflict between Russia and Ukraine, and the resulting jump in energy costs, which affected the Paper division the most, due to being the most energy-intensive division.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
8 Feb 2021 08:54

4D Pharma, Merck And Pfizer Ink Trial Collaboration For Carcinoma Drug

4D Pharma, Merck And Pfizer Ink Trial Collaboration For Carcinoma Drug

Read more
3 Feb 2021 11:19

4D Pharma makes progress with MRx0518 development programme

(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced progress on activities in its development programme for its lead immuno-oncology single strain 'live biotherapeutic' candidate MRx0518 on Wednesday.

Read more
3 Feb 2021 10:50

SMALL-CAP WINNERS & LOSERS: Dr Martens Puts Best Foot Forward

SMALL-CAP WINNERS & LOSERS: Dr Martens Puts Best Foot Forward

Read more
3 Feb 2021 09:01

4D Pharma Says MRx0518 Part B Study Enrolment Continues To Progress

4D Pharma Says MRx0518 Part B Study Enrolment Continues To Progress

Read more
18 Dec 2020 10:13

4D Pharma Joins Landmark Study For Parkinson's Treatment Development

4D Pharma Joins Landmark Study For Parkinson's Treatment Development

Read more
26 Nov 2020 10:53

4D Pharma Files US Registration Statement For ADR Programme

4D Pharma Files US Registration Statement For ADR Programme

Read more
9 Nov 2020 17:28

IN BRIEF: 4d Pharma Reports Positive Data From Ongoing MRx051 Trials

IN BRIEF: 4d Pharma Reports Positive Data From Ongoing MRx051 Trials

Read more
22 Oct 2020 15:42

IN BRIEF: 4D Pharma Proposes Merger With Longevity Acquisition

IN BRIEF: 4D Pharma Proposes Merger With Longevity Acquisition

Read more
22 Oct 2020 11:06

UK WINNERS & LOSERS SUMMARY: Shaftesbury Down 13% Amid Fundraise Plans

UK WINNERS & LOSERS SUMMARY: Shaftesbury Down 13% Amid Fundraise Plans

Read more
7 Oct 2020 11:25

4D Pharma Reports Positive Results From Bowel Syndrome Treatment Trial

4D Pharma Reports Positive Results From Bowel Syndrome Treatment Trial

Read more
30 Sep 2020 12:04

IN BRIEF: 4D Pharma Interim Loss Widens On R&D Costs Increase

IN BRIEF: 4D Pharma Interim Loss Widens On R&D Costs Increase

Read more
23 Sep 2020 19:22

UK EXECUTIVE CHANGE SUMMARY: Primorus Adds Three Directors To Board

UK EXECUTIVE CHANGE SUMMARY: Primorus Adds Three Directors To Board

Read more
26 Aug 2020 10:40

UK WINNERS & LOSERS SUMMARY: Provident Financial Up On Better Outlook

UK WINNERS & LOSERS SUMMARY: Provident Financial Up On Better Outlook

Read more
26 Aug 2020 09:41

4D Pharma Says Results In MRx0518, Keytruda Cancer Trial "Encouraging"

4D Pharma Says Results In MRx0518, Keytruda Cancer Trial "Encouraging"

Read more
13 Jul 2020 18:25

UK TRADING UPDATE SUMMARY: Mineral & Financial Invests In Ideon Tech

UK TRADING UPDATE SUMMARY: Mineral & Financial Invests In Ideon Tech

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.